EJHaem · 2026
Durable MRD-Negative Remission With Blinatumomab and Venetoclax in Heavily Pretreated Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Qadir Mohammad Shahzaib, Farooq Shereen, Jamy Omer
Аннотация
INTRODUCTION: Tyrosine kinase inhibitors (TKIs) are standard therapy for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL); however, relapsed or refractory disease remains challenging due to resistance driven by ABL kinase domain mutations.
METHODS: We report the case of a heavily pretreated patient with relapsed/refractory Ph+ ALL treated with blinatumomab and venetoclax without concurrent TKI therapy.
RESULTS: The patient achieved complete remission and remains in a deep, durable remission exceeding 1 year.
CONCLUSION: This case highlights a potential kinase-independent, TKI-free strategy for relapsed/refractory Ph+ ALL, warranting further investigation.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.
METHODS: We report the case of a heavily pretreated patient with relapsed/refractory Ph+ ALL treated with blinatumomab and venetoclax without concurrent TKI therapy.
RESULTS: The patient achieved complete remission and remains in a deep, durable remission exceeding 1 year.
CONCLUSION: This case highlights a potential kinase-independent, TKI-free strategy for relapsed/refractory Ph+ ALL, warranting further investigation.
TRIAL REGISTRATION: The authors have confirmed clinical trial registration is not needed for this submission.